Suppr超能文献

生长激素治疗与矮小相关的困扰:一项随机安慰剂对照试验。

Growth hormone therapy and short stature-related distress: A randomized placebo-controlled trial.

机构信息

The Jesse Z and Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Clin Endocrinol (Oxf). 2019 May;90(5):690-701. doi: 10.1111/cen.13944. Epub 2019 Mar 7.

Abstract

CONTEXT

Growth hormone (GH) treatment of short healthy children is based on the belief that short stature is associated with psychosocial problems and a diminished quality of life.

OBJECTIVE

To determine the impact of GH therapy on psychosocial well-being and the ability of psychological metrics to define short stature-related distress.

METHODS

Sixty prepubertal boys with idiopathic short stature (age: 10.0 ± 1.4 years, height-SDS: -2.38 ± 0.3) were enrolled in this 4-year intervention study (1-year double-blinded, randomized, placebo-controlled [GH/placebo-2:1] and 3-year open-labelled GH therapy). Explicit (conscious/voluntary) psychological metrics (Pediatric Quality of Life Inventory [PedsQL], Silhouette Apperception Test [SAT], Rosenberg Self-Esteem Scale [RSES], Child Behavior Checklist [CBCL]) and implicit (unconscious/involuntary) psychological metrics (Single-Category Implicit Association Test for height [SC-IAT-H], Height Perception Picture Test [HPPT]). Psychosocial evaluations were performed at study entry, after 1 and 4 years.

RESULTS

At study entry, PedsQL of boys with idiopathic short stature was lower than Israeli norms (P = 0.001). After 1-year blinded intervention, only the GH-treated boys improved their actual and anticipated adult height perception (SAT, P < 0.001 and P = 0.022) with reduced short stature-related distress (SC-IAT-H, P < 0.001). At study end, RSES and SC-IAT-H improved significantly (P < 0.001), with no change in PedsQL and CBCL.

CONCLUSIONS

Our finding of improved psychosocial functioning only in the GH-treated boys after 1-year blinded intervention suggests that it was the GH therapy, rather than being enrolled in a clinical trial, which contributed to the outcome. Long-term open-labelled GH treatment significantly improved height perception and self-esteem. Future studies are needed to fully assess the relevance of complementing the routinely used explicit self-report measures with the implicit measures.

摘要

背景

生长激素(GH)治疗身材矮小的健康儿童是基于这样一种信念,即身材矮小与心理社会问题和生活质量下降有关。

目的

确定 GH 治疗对心理社会健康的影响,以及心理测量指标定义与身材矮小相关的痛苦的能力。

方法

60 名患有特发性身材矮小的青春期前男孩(年龄:10.0 ± 1.4 岁,身高 SDS:-2.38 ± 0.3)参加了这项为期 4 年的干预研究(1 年双盲、随机、安慰剂对照[GH/安慰剂-2:1]和 3 年开放标签 GH 治疗)。明确的(有意识/自愿)心理测量指标(儿科生活质量问卷[PedsQL]、剪影感知测试[SAT]、罗森伯格自尊量表[RSES]、儿童行为检查表[CBCL])和隐含的(无意识/非自愿)心理测量指标(单一类别内隐联想测试身高[SC-IAT-H]、身高知觉图片测试[HPPT])。在研究开始时、1 年后和 4 年后进行心理社会评估。

结果

在研究开始时,特发性身材矮小男孩的 PedsQL 低于以色列标准(P=0.001)。经过 1 年的盲法干预,只有接受 GH 治疗的男孩改善了他们对实际和预期成人身高的感知(SAT,P<0.001 和 P=0.022),减少了与身材矮小相关的痛苦(SC-IAT-H,P<0.001)。在研究结束时,RSES 和 SC-IAT-H 显著改善(P<0.001),而 PedsQL 和 CBCL 没有变化。

结论

我们发现,在 1 年的盲法干预后,接受 GH 治疗的男孩的心理社会功能仅得到改善,这表明是 GH 治疗而不是参加临床试验导致了这一结果。长期开放标签 GH 治疗显著改善了身高感知和自尊。需要进一步的研究来充分评估将常规使用的明确自我报告措施与隐含措施相结合的相关性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验